ValiRx PLC
EAJF
Company Profile
Business description
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Contact
Chelmsford Road
Stonebridge House
Hatfield HeathEssexCM22 7BD
GBRT: +44 1157840025
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
We view the shares are materially overvalued.
stocks
Chart of the Week: Lithium is rebounding on rising demand
The mining sector is significantly overvalued on average but select value to be found.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.60 | 23.80 | -0.25% |
| CAC 40 | 8,398.78 | 30.25 | -0.36% |
| DAX 40 | 25,043.57 | 234.64 | -0.93% |
| Dow JONES (US) | 49,395.16 | 267.50 | -0.54% |
| FTSE 100 | 10,627.04 | 59.14 | -0.55% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,682.73 | 70.91 | -0.31% |
| Nikkei 225 | 57,467.83 | 323.99 | 0.57% |
| NZX 50 Index | 13,371.80 | 72.40 | -0.54% |
| S&P 500 | 6,861.89 | 19.42 | -0.28% |
| S&P/ASX 200 | 9,086.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |